MODERNA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 132.9 USD | +0.17% |
|
+13.29% | +33.63% |
| May. 17 | Moderna Insider Sold Shares Worth $1,912,350, According to a Recent SEC Filing | MT |
| May. 17 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 4.18B | Sales 2025 * | 4.84B | Capitalization | 50.93B |
|---|---|---|---|---|---|
| Net income 2024 * | -2.7B | Net income 2025 * | -1.97B | EV / Sales 2024 * | 10.7 x |
| Net cash position 2024 * | 6.25B | Net cash position 2025 * | 3.94B | EV / Sales 2025 * | 9.71 x |
| P/E ratio 2024 * |
-18.8
x | P/E ratio 2025 * |
-25.9
x | Employees | 5,600 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.41% |
More Fundamentals
* Assessed data
More news
Latest transcript on Moderna, Inc.
More recommendations
More press releases
More news
| 1 day | +0.17% | ||
| 1 week | +13.29% | ||
| Current month | +20.48% | ||
| 1 month | +28.48% | ||
| 3 months | +50.39% | ||
| 6 months | +73.86% | ||
| Current year | +33.63% |
1 week
119.03
134.60
1 month
99.30134.60
Current year
84.06134.60
1 year
62.55142.79
3 years
62.55497.49
5 years
11.54497.49
10 years
11.54497.49
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 51 | 11-02-28 |
James Mock
DFI | Director of Finance/CFO | 47 | 22-09-05 |
Stephen Hoge
PSD | President | 48 | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul Sagan
BRD | Director/Board Member | 65 | 18-05-31 |
| Director/Board Member | 74 | 20-06-30 | |
Francois Nader
BRD | Director/Board Member | 67 | 19-12-10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 5.66% | 0 M€ | 0.00% | - | |
| 4.69% | 2 M€ | -.--% | ||
| 4.08% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 132.9 | +0.17% | 2,718,168 |
| 24-05-16 | 132.7 | +2.80% | 3,008,046 |
| 24-05-15 | 129.1 | +0.58% | 2,964,702 |
| 24-05-14 | 128.3 | +2.11% | 3,625,381 |
| 24-05-13 | 125.7 | +7.13% | 4,095,239 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotes
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
2024-05-31
- Bernstein Strategic Decisions Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
132.9
USD
Average target price
138.5
USD
Spread / Average Target
+4.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +33.63% | 50.93B | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +24.73% | 12.17B | |
| +28.31% | 12.16B | |
| -6.26% | 11.42B |
- Stock Market
- Equities
- MRNA Stock